Pre-launch Intelligence: Unlocking Rx Decisions in Multiple Myeloma

Decoding 2L Prescribing Decisions Before the Label Exists

A Patient Scribe pre-launch intelligence report across five hematology/oncology cases — what five oncologist conversations revealed about 2L prescribing logic in RRMM, where the Dara+Teclistamab regimen fits before a single prescription is written, and what that means for commercial strategy at launch.

About This Report

This report presents findings from five Patient Scribe conversations with hematologist-oncologists managing Relapsed/Refractory Multiple Myeloma patients — conducted before the Darzalex+Teclistamab regimen received approval for the 2L setting. Rather than asking physicians to select from predetermined categories, Patient Scribe conducted a voice-first conversation — capturing clinical reasoning in the physician’s own words, probing when something unexpected surfaced, and structuring the output without compressing the underlying logic. What those conversations surfaced is the kind of pre-launch intelligence that no traditional PCA is designed to collect — the commercial story forming before the first script is written.

WHAT THIS REPORT COVERS

• 5 oncologist conversations via Patient Scribe — hematology / oncology
• Pre-launch intelligence on the Dara+Teclistamab regimen (Darzalex + Tecvayli) in 2L RRMM
• Regimens in scope: Dara+Teclistamab (Darzalex + Tecvayli) · CAR-T (Carvykti · Abecma) · Standard triplets
• Patients ranging from DARA-naive to heavily DARA-exposed in first-line therapy
• Includes cases where Dara+Tec was hypothetically assessed — and what determined the fit
• Note: physicians are responding to a hypothetical approval scenario, not current prescribing experience

 Patients range from DARA-naive to heavily DARA-exposed in first-line therapy — spanning standard and high-risk disease, biochemical and clinical relapse, and a mix of 2L outcomes including CAR-T, novel triplets, and deferred regimens. Three of five were already DARA-exposed, shaping the Dara+Teclistamab addressable pool before any prescribing data exists.  

What a Traditional PCA Would Have Captured

Below is a direct comparison for two of the five cases: what a checkbox-based PCA would have recorded versus what the Patient Scribe conversation actually revealed. The structured data is not wrong — it is structurally incomplete in ways that matter commercially, and incapable of capturing pre-launch intelligence by design.

The checkbox captures the 2L outcome. The conversation captures the commercial story underneath it — including the market taking shape around a regimen not yet on formulary.

What Patient Scribe Revealed

Across conversations, four distinct insight categories emerged that a traditional PCA would have flattened, missed, or been unable to collect.

1. The DARA Exposure Wall — Trial Population Meets Real-World Practice

Of five patients in this dataset, three were already DARA-exposed from first-line therapy. None of the five physicians needed to be asked about the trial population mismatch — they raised it directly when evaluating Dara+Teclistamab. The Majestic-9 trial enrolled primarily DARA-naive patients; the oncologists in this study are managing DARA-exposed patients as the current 1L standard. A traditional PCA records which drug is prescribed. It cannot surface the pre-launch insight that the trial population and the real-world population have already diverged.

• P1: Physician raised the DARA exposure and insurance question unprompted when evaluating the combination — flagging an evidence gap between trial enrollment and real-world practice that no structured field is designed to capture.
• P3: Patient arrived at 2L already DARA-exposed from quad induction — making her a non-candidate for Dara+Tec under trial-consistent criteria. This clinical exclusion is invisible in the current Rx field, which shows only a Carvykti initiation.
• P5: DVRD frontline therapy left the patient DARA + Velcade-refractory. KPD was the logical next step. The DARA exposure that foreclosed re-treatment options appears nowhere in the switch reason field.
• P2: Physician explicitly cautioned against using Dara+Tec prior to BCMA CAR-T — a sequencing concern raised unprompted that will shape the patient selection logic before any guideline formally addresses it.
• P3: "Rapid progressors" and patients who "can’t wait for CAR-T manufacturing" framed as the primary Dara+Tec indication. The physician’s mental model is already built; it will determine patient selection well before prescribing data confirms it.
• P1: For a fit, high-risk patient who wanted a treatment-free interval, CAR-T was selected as “most aligned with goals of care.” The same physician identified the mirror case: patients who cannot manage the CAR-T logistics and would accept a chronic but lower-commitment alternative.
• P1: Treatment goals stated explicitly: “reasonable tolerability, durable remission, treatment-free interval.” CAR-T chosen because patient was motivated and aligned with those goals. The same physician framed the Dara+Tec alternative: patients who prefer chronic maintenance over the logistics and upfront risk of CAR-T.
• P3: Academic center slot access named as a key enabler alongside clinical eligibility — a factor that would reverse the decision in a community setting without CAR-T infrastructure. The structured record does not capture what enabled the choice, only what the choice was.
• P2: Physician treating an older patient with indolent biochemical relapse named guideline inclusion and peer adoption — not trial data — as the primary requirements before broader consideration. The skepticism is not clinical; it is structural.
• P4: Community vs. academic divide named explicitly when evaluating Dara+Tec: standard triplets expected to "remain preferred for broader community use, with combination use more selectively at experienced centers." This structural adoption pattern is forming now.
• P5: Positioned Dara+Tec as a go-to option specifically for patients who have not been exposed to DARA in frontline. A clean, defined inclusion criterion — and one that excludes the majority of current 2L RRMM patients in high-volume practices.

 “Given most of the patients in this trial were DARA naive — the patients I’m going to be writing it for are DARA exposed. The insurances would need to pay for it. We don’t know what the additional benefit is.” 
— Oncologist, RRMM patient audit (P1) 

2. CAR-T Is the Primary Reference Frame

In every conversation where Dara+Teclistamab was evaluated, CAR-T was the first reference point. Physicians did not assess the combination in isolation — they located it relative to CAR-T eligibility, BCMA sequencing risk, and CAR-T manufacturing timelines. The primary use case that emerged consistently: patients who cannot wait for CAR-T, or who are not CAR-T candidates. For eligible patients, the choice between the two is already being made on clinical and patient-preference criteria that do not appear in any structured data field.

“I think second line is the one that was most studied, and I think this is the one place where you can get efficacy that’s comparable to CAR-T.” 
— Oncologist, RRMM patient audit (P3)

3. When Both Options Are Viable, Goals Decide

For patients who qualify for both CAR-T and Dara+Teclistamab, the deciding factor in this dataset was not clinical differentiation — it was patient goals and logistics tolerance. The treatment-free interval expected from CAR-T versus the chronic but lower-upfront-commitment structure of Dara+Tec creates a distinct decision framework that no checkbox is designed to capture. Two patients in this dataset present this exact choice. Neither case would reveal the decision logic from prescribing data alone.

“Some people would really want the chance for a treatment-free interval, which you wouldn’t get with this regimen but you would with CAR-T. And then there might be people that don’t want to deal with the logistics or risks of CAR-T, and would prefer something that’s chronic but less buy-in upfront.” 
— Oncologist, RRMM patient audit (P1)

4. Pre-Launch Niche Formation - The Market Is Being Pre-Sorted Before Approval

Four of five physicians positioned Dara+Teclistamab as a targeted option for specific patient subgroups — not a broad 2L standard. This positioning is happening before a single prescription is written. A commercial divide is already forming between academic centers, where CRS management infrastructure and experienced oncology teams exist, and community practices, where standard triplets are expected to remain the 2L default. Neither the niche positioning nor the academic/community divide will appear in early launch prescribing data.

“I’m quite comfortable with it. I think the Majestic-3 trial data are quite validating. I maybe just want more experience with more patients or full-scale options.” 
— Oncologist, RRMM patient audit (P3) — academic medical center

“Cautiously optimistic. The early efficacy signals are surely compelling for higher-risk or early-relapsing patients, but I wouldn’t necessarily replace established second-line triplets for everyone.” 
— Oncologist, RRMM patient audit (P4) — community / specialty practice

Patient Cases and Commercial Implications 

 The addressable pool is smaller than the label implies

COMMERCIAL IMPLICATION 
Three of five patients in this dataset were DARA-exposed in first-line therapy — making them non-candidates for Dara+Tec under trial-consistent criteria. None of the three are captured by any structured field as Dara+Tec - ineligible; they simply appear as patients on other 2L regimens. Without the conversation, the mismatch between who the trial enrolled and who the physician will actually treat is invisible. The 2L label is not the same as the 2L addressable market.

PATIENT 3 — 63F, HIGH-RISK RRMM, DVRD-EXPOSED, EARLY RELAPSE → CARVYKTI

Bilateral disease, aggressive from diagnosis. DVRD quad induction (4 cycles), then early relapse on maintenance. Extramedullary disease present. Treated at an academic medical center.

DARA exposure in 1L foreclosed Dara+Tec consideration directly. CAR-T slot availability at the academic center was the enabling factor alongside clinical eligibility. The physician has already built the Dara+Tec decision tree: patients who are CAR-T ineligible, or who have aggressive disease and cannot wait for manufacturing. The structured record shows a Carvykti prescription. It does not show the patient profile for which Dara+Tec would have been the alternative — or why this patient did not qualify for it.

PATIENT 5 — 67M, STANDARD RISK, DVRD-EXPOSED → KPD

Clinical relapse after 12 months of DVRD frontline therapy. DARA + Velcade-refractory. Comorbidities: thrombocytopenia, hypertension, diabetes. ECOG 1.

DVRD frontline therapy left this patient DARA + Velcade-refractory. KPD was prescribed as “the standard second-line regimen” — the logical next step given which classes were exhausted. Physician positioned Dara+Tec only for patients who did not receive DARA in frontline, or who were off DARA for maintenance and are now progressing. This patient is the rule, not the exception. The structured record shows a KPD initiation. The conversation shows exactly why DARA re-treatment was not on the table.

CAR-T eligibility is the gating question

COMMERCIAL IMPLICATION 
For the two CAR-T-eligible patients in this dataset, the prescribing logic ran through a goals-of-care conversation, not a clinical algorithm. Physicians assessed patient fitness, preference for treatment-free intervals, and logistics tolerance — none of which appear in structured prescribing data. Dara+Tec enters the conversation as the option for patients who cannot meet or do not want the CAR-T bar. The commercial opportunity is not head-to-head positioning against CAR-T. It is owning the cases where CAR-T is delayed, ineligible, or logistically inaccessible — and those cases are already being defined before approval.

PATIENT 1 — 67M, HIGH RISK, IMID + PI + ANTI-CD38-EXPOSED → CAR-T

Full three-class 1L exposure over 1.5 years, no treatment-free interval. High-risk disease. Motivated patient, goals aligned with CAR-T outcomes.

The prescribing conversation ran through patient goals, not a clinical algorithm: the treatment-free interval was the deciding factor, and the patient was motivated and aligned. The physician named the mirror case explicitly: patients who cannot manage the CAR-T logistics, proximity requirements, and upfront hospitalization risk would logically land on the Dara+Teclistamab regimen instead. Two distinct patient archetypes, one prescribing data field. “You have to be, in my opinion, fit enough for CAR-T” — what sits on either side of that fitness gate is a commercial story, not a clinical one.

The niche is forming at specialty centers — community practices are waiting

 COMMERCIAL IMPLICATION
Two physicians — one at a community practice, one at a specialty center — independently described a consistent commercial reality forming before approval: Dara+Tec will gain traction at centers with CRS management infrastructure, while standard triplets remain the default in broader community settings. Neither physician was asked about practice setting; both raised it in the context of their Dara+Tec assessment. Guideline inclusion and peer adoption were named as the two primary requirements for wider uptake. The physicians who are already comfortable with the data are at academic or specialty centers. The broader community is waiting to be shown, not told. 

PATIENT 2 — 79M, DARA-NAIVE, INDOLENT BIOCHEMICAL RELAPSE → TRIPLET

Long disease history (diagnosed 2018). VRD + ASCT + maintenance Revlimid (~3 years), followed by a 3–4 year treatment-free interval. Late 70s. Biochemical relapse only, no clinical disease.

Age and disease indolence explicitly factored into the choice of a triplet over more aggressive therapy — “did not necessarily warrant quadruplet therapy.” For Dara+Tec: wants guideline inclusion and real-world experience before broader consideration. “I could see it in a subset of patients, although I would want to have more experience with it and make sure it is in guidelines before broader use.” This physician is not skeptical of the data. They are waiting for the ecosystem to validate it.

PATIENT 4 — 68M, LENA-REFRACTORY RRMM, DARA-NAIVE 1L → DKD

Biochemical + symptomatic relapse (worsening bone pain) after PI-based 1L without DARA. Good performance status. Lives near infusion center. Lenalidomide-refractory.

DKD chosen over an alternative triplet specifically to “regain disease control quickly while maintaining tolerability.” Speed was the criterion. The selection process — one regimen considered and deprioritized, one chosen for a specific reason — is invisible in the prescribed drug name. Pre-launch view: the Dara+Teclistamab regimen is targeted for fit, Lena-refractory, high-risk patients. But the adoption ceiling is not a clinical one: it is infrastructure. The physicians who will adopt early are at centers equipped to manage CRS and immunosuppression. Those who are not will wait for the guideline to arrive.

Conclusion 

Five conversations. Five sets of clinical reasoning that a traditional PCA would have recorded as drug names, disease classifications, and switch reasons. What Patient Scribe surfaced instead was the logic underneath each of those data points — the DARA exposure in first line that made three of five patients ineligible for a 2L regimen not yet approved, the CAR-T eligibility gate that determines where the Dara+Teclistamab regimen enters the conversation, the patient goals that drive the choice when both options are clinically defensible, and the community-versus-academic divide forming before the regimen has a label. 

The structured data is not wrong. It is structurally incomplete in ways that matter commercially. Three Dara+Teclistamab non-candidates appear in prescribing data as standard 2L initiations — invisible as ineligible without the conversation. A regimen positioned as a broad 2L option will be received as a niche option in practices where frontline DARA exposure is already the standard. The community/academic adoption gap is forming now, not at launch. These are not edge cases. They are the commercial reality that checkbox formats were never designed to surface. 

This report is part of the ZoomRx Indication Pulse Series — pre-launch and post-launch intelligence across indications where clinical reasoning at the point of prescribing is shaping commercial outcomes before structured data can surface it. 

See What Patient Scribe Would Uncover for Your Brand

ZoomRx is offering a zero-cost pilot wave for teams who want to see what Patient Scribe surfaces for their brand. Same rigor as a full PCA study, no commitment required.